Arrowhead Pharmaceuticals, Inc.

ARWR

US04280A1007

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 20:24:08 23/06/2025 BST			5-day change	1st Jan Change
15.56 ^USD	+1.57%		-1.11%	-17.42%

06-18	Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	RE
06-18	Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	RE

Arrowhead Pharmaceuticals' Plozasiran Lowers Triglycerides in Phase 3 Trial; Shares Rise

Published on 03/06/2024 at 15:37, updated on 03/06/2024 at 15:39

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Arrowhead Pharmaceuticals, Inc.

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	06-18	RE
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	06-18	RE
Arrowhead Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02:00 PM	06-09
Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of Aro-Alk7 for the Treatment of Obesity	06-02	CI
Arrowhead Pharmaceuticals Initiates Phase 1/2A Study Of Aro-Alk7 For The Treatment Of Obesity	06-02	RE
Arrowhead Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 11:20 AM	05-14
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating	05-14	MT
RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating	05-13	MT
Arrowhead Pharmaceuticals, Inc., Q2 2025 Earnings Call, May 12, 2025	05-12
Arrowhead Pharmaceuticals Swings to Fiscal Q2 Earnings; Shares Rise After Hours	05-12	MT
Earnings Flash (ARWR) Arrowhead Pharmaceuticals Posts Q2 Revenue $542.7M	05-12	MT
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025	05-12	CI
Arrowhead Pharmaceuticals Names Daniel Apel Chief Financial Officer	04-15	MT
Arrowhead Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective May 13, 2025	04-15	CI
Arrowhead Pharmaceuticals Says Ken Myszkowski To Retire As CFO	04-15	RE
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,533,337, According to a Recent SEC Filing	04-14	MT
Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	04-04	RE
Arrowhead Pharmaceuticals Insider Sold Shares Worth $774,975, According to a Recent SEC Filing	03-17	MT
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients	03-10	MT
Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy	03-10	RE
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy	03-10	CI
Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment	03-06	MT
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases	03-06	CI
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome	02-28	CI
Arrowhead Pharmaceuticals, Inc. Presents Preclinical Data on Aro-Alk7 for Treatment of Obesity	02-25	CI

Chart Arrowhead Pharmaceuticals, Inc.

Duration

Period

ARWR: Dynamic Chart

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

609

Sector

Biotechnology & Medical Research

Calendar

08-10 - Q3 2025 Earnings Release (Projected)

More about the company